@fgbonadonna.bsky.social
FGB promotes therapeutic innovation from the earliest phases of research and the education of new generations of physician-scientists in Oncology
Addition of carboplatin to sequential taxane-anthracycline neoadjuvant therapy increased overall survival in premenopausal women with triple-negative breast cancer
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #Oncology #CancerResearch @mauriziocallari.bsky.social
A combination of nivolumab and ipilimumab is associated with a high rate of durable responses in mismatch repair–deficient/microsatellite instability–high non colorectal cancers
fondazionebonadonna.org/en/a-combina...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
A promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in non-small-cell lung cancer patients with active brain metastases
fondazionebonadonna.org/en/efficacy-...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
On the occasion of World Cancer Day 2026, #FGB, with the support of the Prada Group and in collaboration with #ESO, announces the 3 winners of the fifth edition of the Fellowship named after Gianni Bonadonna. Press Release fondazionebonadonna.org/wp-content/u...)
#FondazioneBonadonna #PradaGroup
A new phase 3 trial shows the non-inferiority of three versus six months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in colorectal cancer fondazionebonadonna.org/en/three-ver...
#FondazioneBonadonna #Oncology #CancerResearch
In a phase 1 trial, universal base-edited CAR7 T cells induced remission in relapsed or refractory acute lymphoblastic leukemia allowing a successful stem-cell translplantation in most patients
fondazionebonadonna.org/en/universal...
#FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social
Sacituzumab govitecan as first-line therapy showed a significantly longer progression-free survival than chemotherapy in patients with advanced triple-negative breast cancer
fondazionebonadonna.org/en/sacituzum...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer
fondazionebonadonna.org/en/disease-f...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
In patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab improved disease-free survival and overall survival
fondazionebonadonna.org/en/a-ctdna-g...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer
fondazionebonadonna.org/en/capivaser...
#FondazioneGianniBonadonna #CancerResearch #Oncology
@mauriziocallari.bsky.social
In a phase 3 trial the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved clinical outcome in patients with advanced head and neck cancer
fondazionebonadonna.org/en/neoadjuva...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Adjiuvant abemaciclib added to endocrine therapy improves overall survival in patients with HR+/HER2- high risk early breast cancer
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Results from TUXEDO-3 phase 2 trial show a promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in breast cancer patients with acrive brain metastases
fondazionebonadonna.org/en/patrituma...
#FondazioneBonadonna #CancerResearch
@mauriziocallari.bsky.social
A new study identifies 7 tumor microenvironment types and shows how they can shape therapeutic response, recurrence and metastases development in breast cancer
fondazionebonadonna.org/en/the-relev...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social #Bianchini #Criscitiello
A lot of advances have emerged from the Joint International Conference 2025 Innovation in Oncology organized by FGB with Prada Group supporting partner, by Fondazione Michelangelo and by European School of Oncology
fondazionebonadonna.org/en/from-new-...
#FondazioneGianniBonadonna #CancerResearch
The Godard Cinema of Fondazione Prada hosted today the opening press conference of the “Joint International Conference 2025”. The event is organized by FGB with the support of #PradaGroup #FondazioneMichelangelo and @ESOncology .
fondazionebonadonna.org/wp-content/u...
#CancerResearch #Oncology
mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade
fondazionebonadonna.org/en/sars-cov-...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
Capivasertib added to abiraterone with androgen deprivation therapy increases progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer
fondazionebonadonna.org/en/capivaser...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance of gene expression profiling in HER2+ breast cancer, validating the potential of non-chemotherapy approaches in selected patients
fondazionemichelangelo.org/it/notizie-e...
#FondazioneMichelangelo #CancerResearch
Adding radiotherapy to immunotherapy can have systemic immunomodulatory and antitumor effects and may be a way to overcome immunotherapy resistance in non-small cell lung cancer
fondazionebonadonna.org/en/pembroliz...
#FondazioneBonadonna #Oncology
@mauriziocallari.bsky.social
A phase 2 study with the antibody-drug conjugate patritumab deruxtecan showed promising activity and manageable tolerability in patients with HR+/HER2− metastatic breast cancer
fondazionebonadonna.org/en/patrituma...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Analysis of the NeoTRIP trial showed that tumor-specific MHC-II expression is associated with improved response to neoadjuvant chemo-immunotherapy in early triple negative breast cancer
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #CancerResearch
@mauriziocallari.bsky.social
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, shows a predictable safety profile and a promising antitumor activity in metastatic colorectal cancer
fondazionebonadonna.org/en/the-antib...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Camizestrant in association with abemaciclib, palbociclib or ribociclib shows a well-tolerated safety profile and encouraging clinical activity in heavily pretreated advanced breast cancer
fondazionebonadonna.org/en/camizestr...
#Oncology #CancerResearch
@mauriziocallari.bsky.social
Phost’in Therapeutics and Fondazione Gianni Bonadonna to present first clinical data on PhOx430, a First-In-Class GnT-V inhibitor, at @myesmo.bsky.social 2025. Press release fondazionebonadonna.org/wp-content/u...
#PhostInTherapeutics #FondazioneBonadonna #therapeuticinnovation #CancerResearch
Respiratory viral infections can lead to loss of the pro-dormancy phenotype in disseminated #BreastCancer cells in the lung, causing proliferation and expansion of carcinoma cells within days
fondazionebonadonna.org/en/metastati...
#FondazioneBonadonna #Oncology
@mauriziocallari.bsky.social
The ATRACTIB phase 2 trial shows clinical benefit with a combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment in advanced triple-negative breast cancer
fondazionebonadonna.org/en/atezolizu...
#FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social
A dual HER2-targeted blockade with neoadjuvant pyrotinib and ARX788, a new antibody-drug conjugate, as a promising strategy in early or locally advanced HER2-positive breast cancer
fondazionebonadonna.org/en/pyrotinib...
#FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social
Milan to host the Joint Conference 2025 on New Drugs and the Impact of AI in Oncology, organized by FGB with the Prada Group as supporting partner, Fondazione Michelangelo and @ESOncology .
Press Release fondazionebonadonna.org/area-press/
#FondazioneGianniBonadonna #FondazioneMichelangelo
SERENA-6 trial shows a longer progression-free survival with camizestrant added to a CDK4/6 inhibitor in advanced breast cancer with an ESR-1 mutation emerged during treatment fondazionemichelangelo.org/news-update/...
#FondazioneBonadonna #FondazioneMichelangelo #CancerResearch #Oncology
